{"id":198798,"date":"2024-11-04T19:23:08","date_gmt":"2024-11-05T01:23:08","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2024\/11\/first-data-emerges-from-direct-to-brain-alzheimers-stem-cell-therapy-trial"},"modified":"2024-11-04T19:23:08","modified_gmt":"2024-11-05T01:23:08","slug":"first-data-emerges-from-direct-to-brain-alzheimers-stem-cell-therapy-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2024\/11\/first-data-emerges-from-direct-to-brain-alzheimers-stem-cell-therapy-trial","title":{"rendered":"First data emerges from \u2018direct-to-brain\u2019 Alzheimer\u2019s stem cell therapy trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/first-data-emerges-from-direct-to-brain-alzheimers-stem-cell-therapy-trial2.jpg\"><\/a><\/p>\n<p>The small-scale <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05667649?term=%22Regeneration%20Biomedical%22&rank=1\" target=\"_blank\" rel=\"noreferrer noopener\">FDA-cleared trial<\/a> is designed to evaluate both the safety and initial efficacy of RB-ADSCs in nine patients with Alzheimer\u2019s. Regeneration Biomedical\u2019s CTAD presentation focused on the first three enrolled patients, who each received a single dose of RB-ADSCs delivered directly into the lateral ventricles of the brain using an \u201cOmmaya reservoir\u201d \u2013 a device implanted under the scalp to bypass the blood-brain barrier, a major obstacle in Alzheimer\u2019s treatments.<\/p>\n<p>Biomarker analysis at the 12-week mark demonstrated reductions in both p-Tau and amyloid-beta \u2013 two proteins strongly associated with Alzheimer\u2019s disease progression. In cerebrospinal fluid (CSF) samples from the three patients, p-Tau levels decreased to \u201cnormal\u201d levels, while amyloid PET scans also showed a reduction in amyloid buildup.<\/p>\n<p>Regeneration Biomedical also reported its treatment produced signs of cognitive improvement, with two of the three patients showing increased Mini-Mental State Examination (MMSE) scores, a common measure of cognitive function.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The small-scale FDA-cleared trial is designed to evaluate both the safety and initial efficacy of RB-ADSCs in nine patients with Alzheimer\u2019s. Regeneration Biomedical\u2019s CTAD presentation focused on the first three enrolled patients, who each received a single dose of RB-ADSCs delivered directly into the lateral ventricles of the brain using an \u201cOmmaya reservoir\u201d \u2013 a [\u2026]<\/p>\n","protected":false},"author":692,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-198798","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/198798","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/692"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=198798"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/198798\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=198798"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=198798"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=198798"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}